[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642101":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":39,"collaborators":41,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":90,"sex":96,"minAge":97,"maxAge":25,"enrollmentInfo":98,"targetDuration":25,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":118,"overallStatus":122,"whyStopped":25,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":25},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo group","EXPERIMENTAL","vitamin K antagonist with placebo",[13],"Drug: Warfarin (INR 2-3) with placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Aspirin group","ACTIVE_COMPARATOR","vitamin K antagonist with aspirin",[19],"Drug: Warfarin (INR 2-3) with aspirin",[21,26],{"type":22,"name":23,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Warfarin (INR 2-3) with placebo",[9],null,{"type":22,"name":27,"description":27,"armGroupLabels":28,"otherNames":25},"Warfarin (INR 2-3) with aspirin",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Kai Chen, Dr","CONTACT","13269333241","ck_2003@126.com",{"name":36,"role":32,"phone":37,"phoneExt":25,"email":38},"Zelin Yin","13321153733","zelin_0823@163.com",{"type":40,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[42,45,47,49,51,53,55,57,59,61,63,65,67,69,71,73,75,77,79,81,84,86],{"name":43,"class":44},"Beijing Anzhen Hospital","OTHER",{"name":46,"class":44},"Wuhan Asia Heart Hospital",{"name":48,"class":44},"Shanghai Zhongshan Hospital",{"name":50,"class":44},"Jiangsu Provincial People's Hospital",{"name":52,"class":44},"Second Hospital of Jilin University",{"name":54,"class":44},"Nanjing First Hospital, Nanjing Medical University",{"name":56,"class":44},"Zhejiang Provincial People's Hospital",{"name":58,"class":44},"Sir Run Run Shaw Hospital",{"name":60,"class":44},"Sichuan Provincial People's Hospital",{"name":62,"class":44},"First Affiliated Hospital Xi'an Jiaotong University",{"name":64,"class":44},"Zhejiang University",{"name":66,"class":44},"First Affiliated Hospital of Xinjiang Medical University",{"name":68,"class":44},"Fuwai Yunnan Cardiovascular Hospital",{"name":70,"class":44},"Guangdong Provincial People's Hospital",{"name":72,"class":44},"Henan Provincial Chest Hospital",{"name":74,"class":44},"Fujian Provincial Hospital",{"name":76,"class":44},"People's Hospital of Xinjiang Uygur Autonomous Region",{"name":78,"class":44},"Union hospital of Fujian Medical University",{"name":80,"class":44},"Ruijin Hospital",{"name":82,"class":83},"The 7th People's Hospital of Zhengzhou","UNKNOWN",{"name":85,"class":44},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"name":87,"class":44},"Xijing Hospital","100642101","phase-4-study-of-aspirin-removal-in-patients-supported-by-the-fully-magnetically-levitated-ch-vad-pump-100642101",false,"NCT07644247","STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump (STAR Trial)","STAR","Inclusion Criteria:\n\n\\-\n\nStudy participants must meet all the following criteria:\n\n1. Age ≥18 years old;\n2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device;\n3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n\\-\n\nStudy participants meet any of the following criteria will be excluded:\n\n1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation;\n2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent;\n3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation);\n4. Inability to take oral medications post-implant through 7 days;\n5. Known allergy to aspirin;\n6. Participation in another clinical investigation that may affect study outcome;\n7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.","ALL","18 Years",{"count":99,"type":100},370,"ESTIMATED","INTERVENTIONAL",[103],"PHASE4","This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.",[106,107,108,109,110,111,112,113,114,115,116,117],"LVAD (Left Ventricular Assist Device) Thrombosis","LVAD","LVAD (Left Ventricular Assist Device)","LVAD-related GI Bleed","Bleeding","Thrombosis","Stroke","Hemocompatibility-related Adverse Event","Ventricular Assist Device","Aspirin","Antiplatelet Therapy","Antithrombotic Therapy",[119,107,112,110,111,120,115,121],"Left ventricular assist device","Hemocompatibility","Antiplatelet","NOT_YET_RECRUITING","2026-06-08",{"date":125,"type":126},"2026-06-12","ACTUAL",{"date":128,"type":100},"2026-06-25",{"date":130,"type":100},"2029-12-31",{"name":5,"class":6}]